Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1992 Jun;83(6):547–558. doi: 10.1111/j.1349-7006.1992.tb00124.x

Basic Design Considerations for Clinical Trials in Oncology

Steven Piantadosi 1, Nagahiro Saijo 2, Tomohide Tamura 2
PMCID: PMC5918883  PMID: 1644658

Full Text

The Full Text of this article is available as a PDF (833.5 KB).

REFERENCES

  • 1. ) Leventhal B. L. and Piantadosi S. ( ed. ). Issues in clinical research . Sem. Oncol , 15 ( 1988. ). [Google Scholar]
  • 2. ) Piantadosi , S.Principles of clinical trial design . Sem. Oncol , 15 , 423 – 433 ( 1988. ). [PubMed] [Google Scholar]
  • 3. ) Meinert , C. L. “ Clinical Trials ” ( 1986. ). Oxford University Press; , Oxford . [Google Scholar]
  • 4. ) Silverman , W. A. “ Human Experimentation: A Guided Step into the Unknown ” ( 1985. ). Oxford University Press; , Oxford . [Google Scholar]
  • 5. ) Armitage , P.The design of clinical trials . Aust. J. Stat. , 21 , 266 – 281 ( 1979. ). [Google Scholar]
  • 6. ) Louis , T. A. , Mosteller , F. and McPeek , B.Timely topics in statistical methods for clinical trials . Annu. Rev. Biophys. Bioeng. , 11 , 81 – 104 ( 1982. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Lewis , J. A.Clinical trials: statistical developments of practical benefit to the pharmaceutical industry (with discussion) . J. R. Stat. Soc. A , 146 , 362 – 393 ( 1983. ). [Google Scholar]
  • 8. ) Peto , R. , Pike , M. C. , Armitage , P. , Breslow , N. E. , Cox , D. R. , Howard , S. V. , Mantel , N. , McPherson , K. , Peto , J. and Smith , P. G.Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design . Br. J. Cancer , 34 , 585 – 612 ( 1976. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. ) Peto , R. , Pike , M. C. , Armitage , P. , Breslow , N. E. , Cox , D. R. , Howard , S. V. , Mantel , N. , McPherson , K. , Peto , J. and Smith , P. G.Design and analysis of randomized clinical trials requiring prolonged observations of each patient: II. Analysis and examples . Br. J. Cancer , 35 , 1 – 39 ( 1977. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. ) Shapiro , S. H. and Louis , T. A. “ Clinical Trials: Issues and Approaches ” ( 1983. ). Marcel Dekker; , New York . [Google Scholar]
  • 11. ) Pocock , S. J. “ Clinical Trials: A Practical Approach ” ( 1983. ). John Wiley & Sons; , New York . [Google Scholar]
  • 12. ) Buyse M. E. , Staquet M. J. and Sylvester R. J. ( ed. ). “Cancer Clinical Trials. Methods and Practice ” ( 1984. ). Oxford University Press; , Oxford . [Google Scholar]
  • 13. ) Leventhal , B. G. and Wittes , R. E. “ Research Methods in Clinical Oncology ” ( 1988. ). Raven Press; , New York . [Google Scholar]
  • 14. ) Byar , D. P. , Simon , R. M. , Friedewald , W. T. , Schlesselman , J. J. , DeMets , D. L. , Ellenberg , J. H. , Gail , M. H. and Ware , J. H.Randomized clinical trials: perspectives on some recent ideas . N. Engl. J. Med. , 295 , 74 – 80 ( 1976. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Freidman , L. M. , Furberg , C. D. and DeMets , D. L. “ Fundamentals of Clinical Trials ” ( 1981. ). John Wright; , Boston . [Google Scholar]
  • 16. ) Office of Technology Assessment, U.S. Congress . The Impact of Randomized Clinical Trials on Health Policy and Medical Practice: Background Paper . OTA‐BP‐H‐22 ( 1983. ). US Government Printing Office; , Washington , D.C . [Google Scholar]
  • 17. ) Bull , J. P.The historical development of clinical therapeutic trials . J. Chronic Dis. , 10 , 218 – 248 ( 1959. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) “Dorland's Medical Dictionary, 27th Edition ” ( 1988. ). W. B. Saunders Co. , Philadelphia . [Google Scholar]
  • 19. ) “Stedman's Medical Dictionary, 25th Edition ” ( 1990. ). Williams and Wilkins; , Baltimore . [Google Scholar]
  • 20. ) Sommer , A. and Zeger , S. L.On estimating efficacy from clinical trials . Stat. Med. , 10 , 45 – 52 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Newcombe , R. G.Explanatory and pragmatic estimates of the treatment effect when deviations from allocated treatment occur . Stat. Med. , 7 , 1179 – 1186 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Gail , M. H.Eligibility exclusions, losses to follow‐up, removal of randomized patients, and uncounted events in cancer clinical trials . Cancer Treat. Rep. , 69 , 1107 – 1112 ( 1985. ). [PubMed] [Google Scholar]
  • 23. ) Byar , D. P.Why data bases should not replace randomized clinical trials . Biometrics , 36 , 337 – 342 ( 1980. ). [PubMed] [Google Scholar]
  • 24. ) Freiman , J. A. , Chalmers , T. C. , Smith , H. , Jr. and Kuebler , R. R.The importance of beta, the type II error and sample size in the design and interpretation of the randomized controlled trial. Survey of 71 “negative” trials . N. Engl. J. Med. , 299 , 690 – 694 ( 1976. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Sackett , D. L.Bias in analytic research . J. Chronic Dis. , 32 , 51 – 63 ( 1979. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Fleiss , J. L. , Tytun , A. and Ury , H. K.A simple approximation for calculating sample size for comparing independent proportions . Biometrics , 36 , 343 – 346 ( 1980. ). [PubMed] [Google Scholar]
  • 27. ) Donner , A.Approaches to sample size estimation in the design of clinical trials — a review . Stat. Med. , 3 , 199 – 214 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Piantadosi , S. “ Clinical Trials Design Program ” ( 1990. ). BIOSOFT; , Cambridge . [Google Scholar]
  • 29. ) Goldstein , R.Power and sample size via MS/PC‐DOS computers . Am. Stat. , 43 , 253 – 260 ( 1989. ). [Google Scholar]
  • 30. ) Sasaki , Y. , Totani , T. , Shinkai , T. , Eguchi , K. , Tamura , T. , Ohe , Y. , Nakagawa , K. and Saijo , N.A phase I study of cis‐diammine (glycolato) platinum (II) (254‐S; NSC 375101D) administered by 5‐day continuous intravenous infusion: pharmacokinetic and pharmacodynamic analysis . Cancer Res. , 51 , 1472 – 1477 ( 1991. ). [PubMed] [Google Scholar]
  • 31. ) Von Hoff , D. D. , Kuhn , J. and Clark , G. M.Design, and conduct of phase I trials . In “ Cancer Clinical Trials: Methods and Practice ,” ed. Buyse M. E. , Staquet M. J. and Sylvester R. J. , pp. 210 – 222 ( 1984. ). Oxford Univ. Press; , Oxford . [Google Scholar]
  • 32. ) Carter , S. K.Clinical trials in cancer chemotherapy . Cancer , 40 , 544 – 557 ( 1977. ). [DOI] [PubMed] [Google Scholar]
  • 33. ) Muggia , F. M. , Rosenzweig , M. , Staquet , M. J. and McGuire , W. P. , Jr.Methodology of phase II clinical trials in cancer . Recent Results Cancer Res. , 53 – 60 ( 1980. ). [DOI] [PubMed]
  • 34. ) Herson , J.Statistical aspects in the design and analysis of phase II clinical trials . In “ Cancer Clinical Trials: Methods and Practice ,” ed. Buyse M. E. , Staquet M. J. and Sylvester R. J. , 239 – 260 ( 1984. ). Oxford Univ. Press; , Oxford . [Google Scholar]
  • 35. ) Fukuda , M. , Shinkai , T. , Eguchi , K. , Sasaki , Y. , Tamura , T. , Ohe , Y. , Kojima , A. , Oshita , F. , Hara , K. and Saijo , N.Phase II study of (glycolate‐O, O′) diammineplatinum (II), a novel platinum complex, in the treatment of non‐small‐cell lung cancer . Cancer Chemother. Pharmacol. , 26 , 393 – 396 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 36. ) Ohe , Y. , Shinkai , T. , Eguchi , K. , Sasaki , Y. , Tamura , T. , Nakagawa , K. , Kojima , A. , Yamada , K. , Oshita , F. , Miya , T. and Saijo , N.Negative phase II study of 5‐fluorouracil with high‐dose lecovorin in non‐small cell lung cancer . Jpn. J. Clin. Oncol. , 20 , 364 – 368 ( 1990. ). [PubMed] [Google Scholar]
  • 37. ) Piantadosi , S. and Dalesio , O.The randomized phase II clinical trial . Eur. Cancer News , 1 , 3 – 4 ( 1988. ). [Google Scholar]
  • 38. ) Simon , R. , Wittes , R. E. and Ellenberg , S.Randomized phase II clinical trials . Cancer Treat. Rep. , 69 , 1375 – 1381 ( 1985. ). [PubMed] [Google Scholar]
  • 39. ) Anscombe , F. J.Sequential medical trials . J. Am. Stat. Assoc. , 58 , 365 – 383 ( 1963. ). [Google Scholar]
  • 40. ) Armitage , P. , McPherson , C. K. and Rowe , B. C.Repeated significance tests on accumulating data . J. R. Stat. Soc. A , 132 , 235 – 244 ( 1969. ). [Google Scholar]
  • 41. ) Wald , A. “ Sequential Analysis ” ( 1947. ). John Wiley & Sons; , New York . [Google Scholar]
  • 42. ) Pocock , S. J.Group sequential methods in the design and analysis of clinical trials . Biometrika , 64 , 191 – 199 ( 1977. ). [Google Scholar]
  • 43. ) O'Brien , P. C. and Fleming , T. R.A multiple testing procedure for clinical trials . Biometrics , 35 , 549 – 556 ( 1979. ). [PubMed] [Google Scholar]
  • 44. ) Hughes , M. D. and Pocock , S. J.Stopping rules and estimation problems in clinical trials . Stat. Med. , 7 , 1231 – 1242 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 45. ) Chang , M. N. , Wieand , H. S. and Chang , V. T.The bias of the sample proportion following a group sequential phase II clinical trial . Stat. Med. , 8 , 563 – 570 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 46. ) Whitehead , J.Designing phase II studies in the context of a programme of clinical research . Biometrics , 41 , 373 – 383 ( 1985. ). [PubMed] [Google Scholar]
  • 47. ) Whitehead , J.Sample sizes for phase II and phase III clinical trials: an integrated approach . Stat. Med. , 5 , 459 – 464 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 48. ) Thall , P. F. , Simon , R. and Ellenberg , S. S.Optimal two stage designs for clinical trials with binary response . Stat. Med. , 7 , 571 – 579 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 49. ) Weiand , S. and Therneau , T.A two stage design for randomized trials with binary outcomes . Controlled Clin, Trials , 8 , 20 – 28 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 50. ) Ellenberg , S. S. and Eisenberger , M. A.An efficient design for phase III studies of combination chemotherapies . Cancer Treat. Rep. , 69 , 1147 – 1152 ( 1985. ). [PubMed] [Google Scholar]
  • 51. ) Herson , J. and Carter , S. K.Calibrated phase II clinical trials in oncology . Stat. Med. , 5 , 441 – 447 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 52. ) Armitage , P.The search for optimality in clinical trials . Int. Stat. Rev. , 53 , 15 – 24 ( 1985. ). [Google Scholar]
  • 53. ) Peto , R.Discussion of ‘On the allocation of treatments in sequential medical trials’ by Bather J. A. and ‘The search for optimality in clinical trials’ by Armitage P. . Int. Stat. Rev. , 53 , 31 – 34 ( 1985. ). [Google Scholar]
  • 54. ) Chalmers , T. C.The control of bias in clinical trials . In “ Clinical Trials: Issues and Approaches ,” ed. Shapiro S. H. and Louis T. A. , pp. 115 – 127 ( 1983. ). Marcel Dekker; , New York . [Google Scholar]
  • 55. ) Green , S. B.Randomized clinical trials: design and analysis . Sem. Oncol. , 8 , 417 – 423 ( 1981. ). [PubMed] [Google Scholar]
  • 56. ) Gehan , E. A. and Freireich , E. J.Non‐randomized controls in cancer clinical trials . N. Engl. J. Med. , 290 , 198 – 203 ( 1974. ). [DOI] [PubMed] [Google Scholar]
  • 57. ) Green , S. B. and Byar , D. P.The effect of stratified randomization on size and power of statistical tests in clinical trials . J. Chronic Dis. , 31 , 445 – 454 ( 1978. ). [DOI] [PubMed] [Google Scholar]
  • 58. ) Palta , M.Investigating maximum power losses in survival studies with nonstratified randomization . Biometrics , 41 , 497 – 504 ( 1985. ). [PubMed] [Google Scholar]
  • 59. ) Bailar , J. C.Patient assignment algorithms: an overview . In “ Proceedings of the 9th International Biometric Conference. Vol. I ,” pp. 189 – 206 ( 1976. ). The Biometric Society; , Raleigh , N.C . [Google Scholar]
  • 60. ) Simon , R.Adaptive treatment assignment methods and clinical trials . Biometrics , 33 , 743 – 749 ( 1977. ). [PubMed] [Google Scholar]
  • 61. ) Kalish , L. A. and Begg , C. B.Treatment allocation methods in clinical trials: a review . Stat. Med. , 4 , 129 – 144 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 62. ) Efron , B.Forcing a sequential experiment to be balanced . Biometrika , 58 , 403 – 417 ( 1971. ). [Google Scholar]
  • 63. ) Pocock , S. J. and Simon , R.Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial . Biometrics , 31 , 103 – 115 ( 1975. ). [PubMed] [Google Scholar]
  • 64. ) Freedman , L. A. and White , S. J.On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial . Biometrics , 32 , 691 – 694 ( 1976. ). [PubMed] [Google Scholar]
  • 65. ) Begg , CD. and Iglewicz , B. A.A treatment allocation procedure for sequential clinical trials . Biometrics , 36 , 81 – 90 ( 1980. ). [PubMed] [Google Scholar]
  • 66. ) Simon , R.Restricted randomization designs in clinical trials . Biometrics , 35 , 503 – 512 ( 1979. ). [PubMed] [Google Scholar]
  • 67. ) Senn , S. J.Covariate imbalance and random allocation in clinical trials . Stat. Med. , 8 , 467 – 475 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 68. ) O'Fallon , J. R.Policies for interim analysis and interim reporting of results . Cancer Treat. Rep. , 69 , 1101 – 1106 ( 1985. ). [PubMed] [Google Scholar]
  • 69. ) Cornfield , J.Recent methodologic contributions to clinical trials . Am. J. Epidemiol , 104 , 408 – 421 ( 1976. ). [DOI] [PubMed] [Google Scholar]
  • 70. ) Berry , D. A.Interim analyses in clinical trials: classical versus Bayesian approaches . Stat. Med. , 4 , 521 – 526 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 71. ) Berry , D. A.Interim analyses in clinical trials: the role of the likelihood principle . Am. Stat. , 41 , 117 – 122 ( 1987. ). [Google Scholar]
  • 72. ) Gail , M. H.Monitoring and stopping clinical trials . In “ Statistics in Medical Research ,” ed. Mike V. and Stanley K. E. , pp. 455 – 484 ( 1982. ). Wiley; , New York . [Google Scholar]
  • 73. ) DeMets , D. L.Practical aspects in data monitoring: a brief review . Stat. Med. , 6 , 753 – 760 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 74. ) Lan , K. K. G. , Simon , R. and Halperin , M.Stochastically curtailed tests in long‐term clinical trials . Comm. Stat. , 1 , 207 – 219 ( 1982. ). [Google Scholar]
  • 75. ) Shinkai , T. , Eguchi , K. , Sasaki , Y. , Tamura , T. , Ohe , Y. , Kojima , A. , Oshita , F. and Saijo , N.A randomized clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non‐small cell lung cancer . Eur. J. Cancer , 27 , 571 – 575 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 76. ) Brown , B. W. , Jr.Statistical controversies in the design of clinical trials . Controlled Clin. Trials , 1 , 13 – 27 ( 1980. ). [Google Scholar]
  • 77. ) Senn , S. J.Cross‐over trials, carry‐over effects and the art of self‐delusion (letter) . Stat. Med. , 7 , 1099 – 1101 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 78. ) U.S. Food and Drug Administration . “ General Considerations for the Clinical Evaluation of Drugs ,” Pub No. HEW (FDA) 77 – 3040 ( 1977. ).
  • 79. ) Byar , D. P. and Piantadosi , S.Factorial designs for randomized clinical trials . Cancer Treat. Rep. , 69 , 1055 – 1063 ( 1985. ). [PubMed] [Google Scholar]
  • 80. ) Hennekens , C. H. and Eberlein , K. A.for the Physician's Health Study Research Group. A randomized trial of aspirin and beta‐carotene among U.S. physicians . Prev. Med. , 14 , 165 – 168 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 81. ) Stampfer , M. J. , Burning , J. G. , Willet , W. , Rosner , B. , Eberlein , K. and Hennekens , C. H.The 2×2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians . Stat. Med. , 4 , 111 – 116 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 82. ) Physicians' Health Study Research Group . Preliminary report: findings from the aspirin component of the ongoing physician's health study . N. Engl. J. Med. , 318 , 262 – 264 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 83. ) Blot , W. J. and Li , J. Y.Some considerations in the design of a nutrition intervention trial in Linxian, People's Republic of China . Natl. Cancer Inst. Monogr. , 69 ( 1985. ). [PubMed] [Google Scholar]
  • 84. ) Hennekens , C. H.Issues in the design and conduct of clinical trials . J. Natl. Cancer Inst. , 73 , 1473 – 1479 ( 1984. ). [PubMed] [Google Scholar]
  • 85. ) Kornitzer , M. , DeBacker , G. , Dramaix , M. , Kittel , F. , Thilly , C. , Graffar , M. and Vuylsteek , K.Belgian heart disease prevention project: incidence and mortality results . Lancet , i , 1066 – 1070 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 86. ) Donner , A. , Birkett , N. and Buck , C.Randomization by cluster . Am. J. Epidemiol. , 114 , 906 – 914 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 87. ) Zelen , M.Play‐the‐winner rule and the controlled clinical trial . J. Am. Stat. Assoc. , 64 , 131 – 146 ( 1969. ). [Google Scholar]
  • 88. ) Robbins , H.Some aspects of sequential design of experiments . Bull. Am. Math. Soc. 58 , 527 – 535 ( 1972. ). [Google Scholar]
  • 89. ) Taves , D. R.A new method of assigning patients to treatment and control groups . Clin. Pharmacol. Ther. , 15 , 443 – 453 ( 1974. ). [DOI] [PubMed] [Google Scholar]
  • 90. ) Brittain , E. and Schlesselman , J. J.Optimal allocation for the comparison of proportions . Biometrics , 38 , 1003 – 1009 ( 1982. ). [PubMed] [Google Scholar]
  • 91. ) Sposto , R. and Krailo , M. D.Use of unequal allocation in survival trials . Stat. Med. , 6 , 119 – 125 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 92. ) Schafer , A.The ethics of the randomized clinical trial . N. Engl. J. Med. , 307 , 719 – 724 ( 1977. ). [DOI] [PubMed] [Google Scholar]
  • 93. ) Burkhardt , R. and Kienle , G.Basic problems in controlled trials . J. Med. Ethics , 9 , 80 – 84 ( 1983. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94. ) Vere , D. W.Problems in controlled trials — a critical response . J. Med. Ethics , 9 , 85 – 89 ( 1983. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95. ) Fukuoka , M. , Furuse , K. , Saijo , N. , Yutaka , N. , Ikegami , H. , Tamura , T. , Shimoyama , M. and Suemasu , K.Randomized trial of cyclophosphamide, doxorubicin and vincristine (CAV) versus cisplatin and etoposide (PE) versus alternation of CAV and PE in small cell lung cancer . J. Natl. Cancer Inst. , 83 , 855 – 861 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 96. ) Machin , D. , Staquet , M. J. and Sylvester , R. J.Advantages and defects of single‐center and multicenter clinical trials . In “ Controversies in Cancer ,” ed. Tagnon H. J. and Staquet M. J. , pp. 7 – 22 ( 1979. ). Masson Publishing; , New York . [Google Scholar]
  • 97. ) Weiss , D. G. , Williford , W. O. , Collins , J. F. and Bingham , S. F.Planning multicenter clinical trials: a biostatistician's perspective . Controlled Clin. Trials , 4 , 53 – 64 ( 1983. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES